Brief: Antios, Assembly Biosciences To Collaborate To Test Combination Of ATI-2173 And Vebicorvir In Patients With Chronic Hepatitis B Virus Infection

Assembly Biosciences

19/10/2021 13:04

Oct 19 (Reuters) - Assembly Biosciences Inc  ASMB.O :
    * ANTIOS THERAPEUTICS AND ASSEMBLY BIOSCIENCES ANNOUNCE
CLINICAL
COLLABORATION AGREEMENT TO EVALUATE THE COMBINATION OF ATI-2173
AND VEBICORVIR IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS
INFECTION
    * ASSEMBLY BIOSCIENCES INC - A SINGLE COHORT IN ONGOING
ANTIOS
PHASE 2A ANTT201 CLINICAL TRIAL WILL EVALUATE ATI-2173
    * ASSEMBLY BIOSCIENCES INC - COHORT IS EXPECTED TO START IN
FIRST
HALF OF 2022

Source text for Eikon:  ID:nGNX5Qwz18 
Further company coverage:  ASMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))